Insertable cardiac monitoring for atrial fibrillation detection was found to be cost-effective, especially among high-risk patients, according to an economic analysis of the STROKE AF trial presented at the International Stroke Conference.
“In a model that assumes that risk of stroke derived from prior studies of AF is applicable to patients with [insertable cardiac monitor]-detected AF, use of [insertable cardiac monitor] as an initial strategy is more cost-effective than usual rhythm monitoring care over a lifetime horizon. This is due to more frequent AF detection with greater and